KUALA LUMPUR, Malaysia, June 26, 2026 /PRNewswire/ -- The 6th Hospitality Malaysia Conference #HMC2026 officially concluded its highly successful run at the Connexion Conference & Event Center Kuala Lumpur, solidifying its position as the premier B2B platform for the country's tourism and accommodation sectors. Organised by Hospitality Asia, the summit brought together a diverse ecosystem of stakeholders under an expanded multi-summit format to address the investment, design, and revenue strategies driving the Malaysian hospitality market forward.
The event achieved unprecedented scale, drawing 351 unique event attendees representing 228 leading companies from 10 countries. While local market dynamics took center stage with 84.1% of delegates hailing from Malaysia, the conference maintained a strong regional footprint with notable participation from Singapore (8.2%), Indonesia (2.3%), Thailand (2.0%), and Japan (1.1%), alongside delegates from the Americas, India, Mainland China, the Philippines, and Australia.
Reflecting the event's high-level networking ecosystem, the business nature breakdown revealed an owner-centric audience: 40.2% represented Asset Ownership, followed by Hotel Management & Operations (16.0%), Technology & Vendors (13.1%), and Design, Build & Project Delivery (11.7%). The remaining delegation comprised government associations, advisory services, institutional investors, media, F&B, wellness, and travel providers.
A Triple-Summit Strategic Agenda
For the 2026 edition, the conference featured three summits, driven by a powerhouse lineup of 81 expert speakers and supported by 43 elite event sponsors & partners.
The Hotel Investment Summit focused heavily on macro-economics, asset valuation, and funding structures. A key highlight was the interactive panel session examining how owners can navigate market volatility and align their portfolios with changing market demands.
"The core value of this summit lies in the collective exchange of experiences, learning from fellow industry leaders, and gaining a precise understanding of modern traveler and guest expectations," noted Andrew Khoo, Chairman and Chief Executive Officer The MUI Group. "The primary challenge within Malaysian hospitality today is establishing meaningful connections with the right partners. We possess industry passion; by bringing the right stakeholders together, we can seamlessly deliver properties that align with the highest guest expectations."
The Hotel Revenue Summit addressed the commercial side of operations, focusing on total revenue management (TRevPAR), dynamic pricing algorithms, and distribution strategies. The panel sessions challenged traditional commercial models, offering fresh operational perspectives for the year ahead.
"My ultimate expectation is to support and elevate the vital groundwork being done by hoteliers across the industry," shared Anshul Kumar, Director of Sales, India and Southeast Asia Aven Hospitality. "This summit presents a remarkable opportunity to gain deeper strategic insights from peers and partners right from within the heart of the sector. It offers a valuable moment to step back, evaluate your overarching strategy, and analyze the way you operate, while simultaneously connecting with the key decision-makers who impact your day-to-day operations."
The Hotel Design Summit explored the physical evolution of spaces, highlighting local craftsmanship, and narrative-driven architecture. The panel discussions focused on maximizing design return on investment (ROI) in both urban conversions and resort spaces.
"Participating in HMC for the first time has provided an invaluable opportunity to gain fresh insights from the panels and view the Malaysian hospitality landscape through a broader strategic lens," stated Ben Gregoire, Founder & Principal of LEVELS. "Networking directly with suppliers, property operators, and asset owners is incredibly beneficial, particularly given the highly unique and diverse tourism assets that Malaysia has to offer."
Driving Tangible Business: Match & Meet and Exhibition Showcase
Beyond the stage discussions, #HMC2026 served as a live marketplace. A major highlight of the event was the dedicated Match & Meet networking sessions, which targeted business matchmaking between pre-qualified delegates, owners, and developers from various sectors.
In tandem, the bustling Exhibition Showcase allowed the event's 43 sponsors and partners to demonstrate cutting-edge solutions and their contribution in hospitality. Delegates engaged directly with leading innovators in technology vendor, payment system, guest-experience services, providing hotel owners and industry people with immediate resources to optimize their properties.
"Marking our inaugural participation at HMC this year, our primary objective was to engage in highly meaningful conversations with the industry stakeholders in attendance," stated Ezra Wang, Director, Travel & Hospitality APAC, Sertifi by Flywire. "We have already concluded several productive meetings with key hotel operators and owners. While today represents the crucial starting point for these dialogues, we are highly optimistic that these initial discussions will soon translate into concrete business decisions and long-term partnerships."
As Malaysia enters its next phase of tourism growth, #HMC2026 has successfully delivered the actionable intelligence, cross-border connections, and strategic partnerships necessary to lead the industry forward.
For post-event highlights and gallery access, please visit: hospitality-malaysia.com
PR Newswire is the Media Partner of Hospitality Malaysia Conference.
About Hospitality Asia
The Hospitality Asia Event Series is a leading platform for senior leaders across the region's hospitality and tourism sectors. It is known for bringing together key decision-makers and industry innovators while creating strong opportunities for networking, knowledge exchange, and strategic collaboration.
The series features seven flagship events across Asia, including the Hospitality Indonesia Conference (HIC), the Hospitality Vietnam Conference (HVC), the Hospitality Thailand Conference (HTC), the Hospitality South Korea Conference (HSKC), the Hospitality Malaysia Conference (HMC), the Hospitality Philippines Conference (HPC) and the Hospitality Japan Conference (HJC). These events attract a high-level and diverse audience from across the region.
Hospitality Asia is distinguished by its balanced engagement of both C-level executives and senior professionals such as Vice Presidents, General Managers and Directors who manage contracts, negotiations and daily operations. Supported by regional advisors who provide real-time market insights, the content focuses on practical strategies that enable participants to drive business growth.
The series is guided by four summits that represent the main drivers of industry success. These include the Hotel Investment Summit Asia #HISA, the Hotel Design Summit Asia #HDSA, the Hotel Revenue Summit Asia #HRSA and the Travel Byte Summit Asia #TBSA. Each summit is delivered with a localized approach to ensure relevance and meaningful engagement with the region's most important opportunities.
To learn more about Hospitality Asia, please visit our website at www.hospitality-asia.com.
CONTACT:
Hospitality Asia Media
Ifnur
ifnur@hospitality-asia.com
Photo: https://drive.google.com/drive/u/0/folders/1h7FmxD3epR4A-oTVj6ox2OPIGCBGBmho
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
6th Hospitality Malaysia Conference #HMC2026 Concludes in Kuala Lumpur, Uniting Regional Power Players to Shape the Future of Hospitality
NANJING, China, June 26, 2026 /PRNewswire/ -- Recently, the NDA for Sumecigrel Capsule (formerly known as Vicagrel), a Class 1 innovative antiplatelet drug developed by Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech), has been officially accepted by the NMPA. The drug has now entered the NDA stage. As a global pioneer in novel antiplatelet agents, Sumecigrel is expected to provide a new and improved treatment option to tens of millions of patients with cardiovascular and cerebrovascular diseases.
Sumecigrel Capsule is a new-generation oral P2Y12 receptor antagonist, clinically indicated for the treatment and prevention of atherosclerotic thrombotic events, including Acute Coronary Syndrome (ACS), Ischemic Stroke (IS) and Peripheral Arterial Disease (PAD). Designed to address the boxed warning regarding clopidogrel resistance, this drug innovatively optimizes the metabolic pathway of clopidogrel while retaining the molecular discovery pathway of its active metabolite. It aims to strike a better balance between the therapeutic benefits and bleeding risks of antiplatelet medications.
A series of completed clinical studies, including Phase I, Phase II, China-US PK/PD bridging study and Phase III trials, have fully validated the clinical efficacy and safety of Sumecigrel Capsule. It boasts multiple advantages including faster onset of action, lower dosage, more stable therapeutic effect, better control of bleeding risks, reduced metabolic burden and broader application scope. The Phase III clinical studies have now been completed. Sumecigrel demonstrated a trend of superior performance over clopidogrel in reducing the risk of MACCE, with more prominent benefits observed in elderly patients, those complicated with anemia, chronic kidney disease and patients undergoing complex PCI with multiple stents, especially high-risk elderly patients aged 75 and above. The drug also shows favorable safety profiles: its major bleeding risk is comparable to that of clopidogrel and better than data from similar studies, with no new unexpected safety signals identified.
Against the backdrop of population aging, clinical challenges such as high bleeding risks and complicated combined medication use among elderly cardiovascular patients have become increasingly prominent. Approximately 30% to 40% of patients struggle to achieve a balance between efficacy and safety, leading to huge unmet clinical needs. Sumecigrel effectively addresses the shortcomings of existing drugs and offers a new therapeutic breakthrough for patients with high-risk and complex conditions.
Dr. Gong Yanchun, Co-founder, Chairman and CEO of Vcare PharmaTech, stated: "Sumecigrel Capsule is an achievement from the industry-university-research cooperation between our company and China Pharmaceutical University in the early stage. After years of intensive R&D efforts, the NDA has now been accepted, marking a critical milestone. The field of cardiovascular and cerebrovascular disease treatment is in urgent need of high-quality innovative drugs with balanced efficacy and safety to cater to increasingly personalized antiplatelet treatment scenarios. We look forward to the successful launch of Sumecigrel Capsule to benefit patients with cardiovascular and cerebrovascular diseases worldwide."
Following the achievement of this key regulatory milestone in China, Vcare PharmaTech will fully advance the subsequent review and approval procedures for marketing. Meanwhile, the company continues to prepare for marketing applications in the United States, the European Union and other countries and regions. In addition, Vcare PharmaTech has entered into an exclusive regional licensing agreement with Everest Medicines for the Asia-Pacific market of Sumecigrel. The company is accelerating the global strategic layout of this product in an all-round manner.
About Sumecigrel
Sumecigrel is the world's first new-generation P2Y12 receptor antagonist developed on the premise of retaining the same active metabolite as clopidogrel and optimizing its metabolic pathway to mitigate clopidogrel's heavy reliance on CYP2C19 genetic polymorphism. It is indicated for atherosclerotic thrombotic events including Acute Coronary Syndrome (ACS), Ischemic Stroke (IS) and Peripheral Arterial Disease (PAD). It stands as one of Vcare PharmaTech's representative achievements under the philosophy of "differentiated original design to address unmet clinical needs".
The molecular design findings of the drug were published in Journal of Medicinal Chemistry (JMC), a top journal of the American Chemical Society, and highlighted by SciBX under Nature Portfolio, being recognized as "one of the most commercially promising projects in the field of new antiplatelet drugs". Currently, its NDA has been accepted in China, and NDA preparations are underway in the United States, the European Union and other regions. With Best-in-Class potential and broad commercial prospects, Sumecigrel is poised to reshape the antithrombotic drug market, which has seen no innovative drugs targeting the same mechanism launched for more than a decade.
About Cardiovascular and Cerebrovascular Diseases
Cardiovascular and cerebrovascular diseases refer to a group of functional and organic disorders of the circulatory system, covering diseases related to the heart, blood vessels and neurohumoral systems regulating blood circulation. According to lesion locations and pathological characteristics, they are generally divided into heart diseases, cerebrovascular diseases (such as stroke) and peripheral vascular diseases, forming a multi-level disease spectrum across the whole circulatory system.
Atherosclerosis is the major pathological basis of these diseases. Lipid deposition, vascular endothelial injury, inflammatory response and thrombosis may cause vascular stenosis, occlusion or decreased elasticity, further leading to severe conditions such as myocardial ischemia, myocardial infarction, cerebral infarction and cerebral hemorrhage. These diseases are featured by high morbidity, disability, mortality, recurrence rate and numerous complications. Major risk factors include hypertension, hyperlipidemia, hyperglycemia, smoking, excessive drinking, sedentary lifestyle, obesity and advanced age. Mostly developing chronically with acute episodes, they rank as the top chronic diseases threatening the health of middle-aged and elderly people.
Cardiovascular and cerebrovascular diseases have become one of the leading causes of death worldwide. The related death toll rose to 17.9 million in 2019, accounting for about 32% of all global deaths in that year, among which around 85% were caused by myocardial infarction (a major type of Acute Coronary Syndrome) and stroke. The latest epidemiological studies show that the death toll from cardiovascular and cerebrovascular diseases further increased to 19.2 million in 2023.
About Vcare PharmaTech
Founded in 2010 by professors from China Pharmaceutical University and overseas returnee talents, Jiangsu Vcare PharmaTech Co.,Ltd. is a commercial-stage innovative bio-pharmaceutical enterprise empowered by AI for differentiated original drug design. The company is dedicated to the development of innovative drugs and cutting-edge therapies.
Headquartered in the Biomedical Valley of Nanjing Jiangbei New Area, Vcare PharmaTech owns a 21,000 square-meter intelligent R&D headquarters. It has built a full-chain innovation system for independent drug R&D and industrialization, covering AI-driven differentiated project initiation, preclinical candidate discovery, integrated drug development and green manufacturing. The company boasts a strong talent team of more than 900 employees, over 84% of whom are technical staff, including more than 200 talents with master's and doctoral degrees. This high-caliber, professional and innovative core R&D team underpins the company's continuous technological breakthroughs and product iteration.
Over sixteen years of dedication to pharmaceutical innovation, Vcare PharmaTech adheres to the core strategy of independent R&D and focuses on addressing unmet clinical needs via differentiated approaches. Centering on overcoming treatment resistance, tackling drug resistance and optimizing target selectivity, the company has established a diversified and high-quality pipeline of innovative drugs covering major chronic disease areas including cardiovascular and cerebrovascular diseases, inflammatory and autoimmune diseases, as well as oncology.
Eratrectinib Capsule, a new-generation TRK inhibitor, is clinically used for patients with solid tumors harboring NTRK gene fusions. It delivers a high tumor response rate and strong anti-resistance performance and has been approved for marketing. Sumecigrel Capsule, a new-generation oral P2Y12 receptor antagonist targeting clopidogrel resistance, has had its NDA accepted in China. VC005, a new-generation highly selective JAK1 inhibitor focusing on inflammatory and autoimmune diseases, is in Phase III clinical trials for atopic dermatitis with both oral and topical formulations developed for all patient groups. It is also being explored for ankylosing spondylitis, vitiligo, alopecia areata and other autoimmune diseases, with promising efficacy and safety data.
Leveraging years of technological accumulation, Vcare PharmaTech strives to integrate AI capabilities across the entire R&D and production chain, and has established an AI-powered advanced drug R&D system and professional technology platforms. The company has been accredited with multiple honors including Nanjing Key Laboratory for AI-Aided Drug Design and Nanjing Engineering Research Center for Synthetic Biology and Flow Chemistry. Its AI-assisted directed enzyme mutation technology was recognized as an Advanced Cleaner Production Technology of Nanjing. The company has raised over 1.2 billion RMB in total financing in the past five years, winning wide recognition from the capital market.
Going forward, adhering to the original aspiration of "The better Care, The better Medicines", Vcare PharmaTech will continue to deepen AI-driven original innovation, make breakthroughs in cutting-edge pharmaceutical technologies and expand its strategic layout at home and abroad. With solid R&D strength and differentiated drug pipelines, the company aims to deliver superior treatment solutions to patients across the globe and grow into a world-class innovative pharmaceutical enterprise.
Commercial Cooperation:
Strategic Development Director: Dr. Peng peng_yuran@vcarepharmatech.com
BD Director: Liam xu_minghua@vcarepharmatech.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Key Milestone Achieved: NDA for Sumecigrel Capsule, an Antiplatelet Innovative Drug by Vcare PharmaTech, Officially Accepted
